Lucid Diagnostics Inc.
LUCD
$1.20
-$0.01-0.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 79.00% | 179.27% | 379.19% | 370.50% | 544.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.00% | 179.27% | 379.19% | 370.50% | 544.03% |
| Cost of Revenue | 18.62% | 3.96% | 3.28% | 36.77% | 64.66% |
| Gross Profit | 23.00% | 52.73% | 52.57% | 16.82% | -8.81% |
| SG&A Expenses | 2.45% | -6.19% | -12.92% | -21.44% | -10.94% |
| Depreciation & Amortization | -70.34% | -46.42% | -24.85% | -9.80% | 20.01% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.20% | -7.82% | -13.70% | -18.65% | -10.10% |
| Operating Income | 5.22% | 13.21% | 19.34% | 22.88% | 13.81% |
| Income Before Tax | 13.55% | 21.05% | 18.01% | 21.81% | 6.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.55% | 21.05% | 18.01% | 21.81% | 6.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.55% | 21.05% | 18.01% | 21.81% | 6.24% |
| EBIT | 5.22% | 13.21% | 19.34% | 22.88% | 13.81% |
| EBITDA | 2.60% | 12.04% | 19.35% | 23.67% | 15.34% |
| EPS Basic | 15.03% | 19.57% | 16.16% | 20.60% | 18.54% |
| Normalized Basic EPS | 29.80% | 27.77% | 31.64% | 34.16% | 24.04% |
| EPS Diluted | 15.03% | 19.57% | 16.16% | 20.60% | 18.54% |
| Normalized Diluted EPS | 29.80% | 27.77% | 31.64% | 34.16% | 24.04% |
| Average Basic Shares Outstanding | 20.95% | 14.73% | 13.30% | 13.63% | 15.43% |
| Average Diluted Shares Outstanding | 20.95% | 14.73% | 13.30% | 13.63% | 15.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |